MarketCap
Facebook
X
TelegramQuarterly report 2026-Q1
added 05-07-2026
Soleno Therapeutics Cost of Revenue 2011-2026 | SLNO
Cost of Revenue is a financial metric that reflects all direct costs associated with the production of goods or the provision of services that directly led to revenue during the reporting period. It is the total amount of expenses incurred by the company to deliver its products or services, including both production costs and related expenses necessary for delivery or customer support.What is included in the cost of revenue
| Cost Category | Examples |
|---|---|
| Production Costs | Materials, wages of production staff, depreciation of equipment |
| Service and Support | Customer service, user support, technical assistance |
| Delivery and Logistics | Packaging, delivery of goods to customers |
| Hosting and Infrastructure | Servers, cloud platforms (especially for IT and SaaS companies) |
| Content and Licenses | License purchases, production royalties (e.g., in streaming services) |
Importance of the Metric
- Helps to understand how costly the revenue-generating process is.
- A high cost of revenue may indicate:
Poor cost control
Low operational efficiency - A low cost of revenue combined with high revenue indicates high profitability and business competitiveness.
Annual Cost of Revenue Soleno Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.7 M | - | - | - | - | - | - | - | - | 1.51 M | 353 K | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 2.7 M | 353 K | 1.52 M |
Quarterly Cost of Revenue Soleno Therapeutics
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.2 M | 1.14 M | 696 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 42 K | 209 K | - | 399 K | 51 K | 461 K | - | 56 K | 22 K | 18 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.2 M | 18 K | 390 K |
Cost of Revenue of other stocks in the Diagnostics research industry
| Issuer | Cost of Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Burning Rock Biotech Limited
BNR
|
144 M | $ 17.26 | -7.0 % | $ 181 M |  China |
 |
Centogene N.V.
CNTG
|
162 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Co-Diagnostics
CODX
|
222 K | $ 1.34 | -17.79 % | $ 1.78 M |  USA |
 |
Fulgent Genetics
FLGT
|
176 M | $ 15.78 | -2.53 % | $ 477 M | USA |
 |
Agilent Technologies
A
|
2.91 B | $ 112.09 | -1.02 % | $ 34.1 B | USA |
 |
Castle Biosciences
CSTL
|
71 M | $ 19.05 | 0.9 % | $ 552 M | USA |
|
Akumin
AKU
|
608 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Aspira Women's Health
AWH
|
3.3 M | - | -6.19 % | $ 10.5 M | USA |
 |
Accelerate Diagnostics
AXDX
|
9.45 M | - | -61.36 % | $ 2.46 M | USA |
 |
Illumina
ILMN
|
1.51 B | $ 139.97 | -2.28 % | $ 22.3 B | USA |
 |
Biocept
BIOC
|
28.4 M | - | -13.05 % | $ 7.29 M | USA |
 |
Interpace Biosciences
IDXG
|
14.6 M | $ 1.8 | -5.26 % | $ 7.96 M | USA |
 |
CareDx, Inc
CDNA
|
45.5 M | $ 19.83 | -3.22 % | $ 1.06 B | USA |
 |
Chembio Diagnostics
CEMI
|
38.6 M | - | 0.22 % | $ 16.8 M | USA |
 |
Lantheus Holdings
LNTH
|
600 M | $ 94.74 | -2.0 % | $ 6.39 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
4.57 M | - | -20.0 % | $ 1.06 M | USA |
 |
Myriad Genetics
MYGN
|
248 M | $ 3.6 | -0.69 % | $ 333 M | USA |
 |
Global Cord Blood Corporation
CO
|
183 M | - | - | $ 399 M | China |
 |
NeoGenomics
NEO
|
413 M | $ 8.28 | -0.96 % | $ 1.06 B | USA |
 |
Genetic Technologies Limited
GENE
|
276 K | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
194 M | - | 0.12 % | $ 80.1 M | China |
 |
DermTech
DMTK
|
15 M | - | -11.32 % | $ 2.94 M | USA |
 |
Natera
NTRA
|
158 M | $ 186.22 | -5.43 % | $ 18.3 B | USA |
 |
Enzo Biochem
ENZ
|
17.3 M | - | -8.98 % | $ 14.8 K | USA |
 |
Koninklijke Philips N.V.
PHG
|
9.78 B | $ 25.27 | -0.94 % | $ 24 B |  Niderland |
 |
Exact Sciences Corporation
EXAS
|
984 M | - | - | $ 19.8 B | USA |
 |
Guardant Health
GH
|
349 M | $ 92.95 | -5.79 % | $ 11.7 B | USA |
 |
Senseonics Holdings
SENS
|
19.5 M | $ 5.73 | -1.55 % | $ 239 M | USA |
 |
Personalis
PSNL
|
53.9 M | $ 6.47 | -3.64 % | $ 577 M | USA |
 |
Heska Corporation
HSKA
|
146 M | - | - | $ 1.31 B | USA |
 |
ICON Public Limited Company
ICLR
|
3.97 B | $ 117.95 | 0.73 % | $ 9.73 B |  Irlanda |
 |
QIAGEN N.V.
QGEN
|
801 M | - | - | $ 10.6 B | Niderland |
 |
Twist Bioscience Corporation
TWST
|
186 M | $ 49.3 | -6.89 % | $ 2.95 B | USA |
 |
Biomerica
BMRA
|
4.81 M | $ 2.31 | -4.04 % | $ 5.31 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
9.94 B | $ 251.18 | -1.12 % | $ 20.9 B | USA |
 |
Trinity Biotech plc
TRIB
|
40.1 M | $ 0.57 | -1.49 % | $ 205 M | Irlanda |
 |
Motus GI Holdings
MOTS
|
81 K | - | -34.28 % | $ 263 K |  Israel |
 |
Waters Corporation
WAT
|
363 M | $ 331.34 | -0.56 % | $ 19.7 B | USA |
 |
Neogen Corporation
NEOG
|
473 M | $ 8.27 | -1.9 % | $ 1.79 B | USA |